Pembrolizumab
nouscom,Merck
['nous,pev', 'nouscom']
#nouscom presents new positive translational phase 1b data of #nouspev, a #personalized #neoantigencancerimmunotherapy, in a late-breaking abstract at #aacr23 
Follow top-line development in the oncology commercial domain through our award winning intelligence service, 1stOncology.